ATLANTA – September 3, 2018
SLAS Discovery, a leading peer-reviewed scientific journal, today released its September, 2018 edition (Volume 23 Issue 8, September 2018), choosing as its cover story a ground-breaking new article titled, “Clinical Trials in a Dish: A Perspective on the Coming Revolution in Drug Development”. Copies of the article – which describes a novel drug safety testing paradigm that bridges the worlds of preclinical testing and clinical trials – can be accessed for free on the publisher’s website at: http://journals.sagepub.com/doi/full/10.1177/2472555218775028.
According to the article – which was co-authored by Bernard Fermini, PhD; Coyne Scientific CEO, Kevin P. Coyne; and Coyne Scientific President, Shawn T. Coyne – the cost of developing new drugs has reached unsustainable levels, fueled in large part by high attrition rates in clinical development. Recent studies have shown that individual drug susceptibility in a population of volunteers with unknown genetic background can be recapitulated in human induced pluripotent stem cells (hiPSCs) derived from these same individuals, providing a proof of concept for in vitro preclinical trials, and enabling cell-based screening for safety and toxicity at the level of a population, similar to clinical trials. This new platform, termed “Clinical Trials in a Dish”, or CTiD, allows researchers to define the incidence and distribution of effects of drugs (whether beneficial or adverse) across a population long before actual clinical trials, so that a pharma company can curtail development of “future failures” early on while continuing development of safe compounds that might not have met traditional safety margins.
CTiD studies, which first became commercially available earlier this year, can also help pharma companies address such important issues as repurposing shelved compounds, reducing adverse drug-drug interactions, protecting underserved ethnic populations, and protecting children and geriatric patients – economically, and without regulatory complications.
To discover how this new platform offers the potential to revolutionize safety and toxicity testing of new drugs, and/or for more information on Coyne Scientific and its services, please contact Shawn T. Coyne, President, at firstname.lastname@example.org.
* * *
ABOUT COYNE SCIENTIFIC, LLC
Coyne Scientific is a biotech services company that conducts in vitro safety and toxicity testing on pharmaceutical compounds. We use human stem cell-based models to demonstrate the range and distribution of toxicity reactions to compounds across a population as a result of that population’s genetic diversity. We can help clients dramatically reduce drug development costs through early identification of compounds that may negatively affect a portion of clinical trial participants despite appearing to be safe to the “average” human. We can also help improve the safety of drugs in cases where large clinical trials are infeasible, such as in the entry of drugs into small national markets with genetically-distinct populations.
For more information, please contact Shawn T. Coyne, President, at email@example.com.